摘要
药物经济学评价是中药上市后再评价的一个重要环节,经过药物经济学的评价能更好的体现中药上市后的临床价值和市场价值,制定《中药上市后药物经济学评价技术规范》,其目的是使中成药药物经济学评价过程及结果更加科学合理。该技术规范参照各国的药物经济学指南,结合中药的特殊性,初步制定适用于已上市中药的药物经济学评价。
Pharmacoeeonomics is an important part of the post-marketing evaluation of Chinese medicine, post-marketing phar- macoeconomic evaluation can better reflect the clinical and market value of Chinese medicine, the purpose of establishing the technical specifications for pharmacoeconomic evaluation is to make the evaluation process and results regarding Chinese patent medicines more scientific and fair. Every country＇s technical specifications for pharmacoeconomic evaluation act as reference guidelines, we have al- ready drawn up the technical specifications which take into account the special characteristics of Chinese medicine; these are in prepa- ration for post-marketing pharmacoeconomic evaluation Chinese medicine.
出处
《中国中药杂志》
CAS
CSCD
北大核心
2013年第18期2925-2929,共5页
China Journal of Chinese Materia Medica
基金
国家"重大新药创制"科技重大专项(2009ZX09502-030)
关键词
上市后中药
药物经济学
技术规范
评价
post-marketing evaluation Chinese medicine
pharmacoeconomics
technical specifications
estimate
